The Netherlands Cancer Institute shared on LinkedIn:
“PERISCOPE II provides important evidence for gastric cancer with limited peritoneal metastases. In this European multicenter randomized controlled trial, adding gastrectomy, cytoreductive surgery, and HIPEC to systemic therapy did not improve overall survival, while treatment-related toxicity was substantially higher in the experimental arm. An important example of why randomized trials matter in guiding patient care.”
Title: Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis
Authors: Judith S. E. Quik, Marieke A. Vollebergh, Valesca P. Retèl, Karen van der Sluis, Willem J. Koemans, Rosa T. van der Kaaij, Madelon M. Voets, Misha D. P. Luyer, Irene E. G. van Hellemond, Bas P. L. Wijnhoven, Bianca Mostert, Richard van Hillegersberg, Nadia Haj Mohammad, Boudewijn van Etten, Derk J. de Groot, Olli Helminen, Jakob Hedberg, Peter H. Cashin, Julie L. Harbjerg, Alexander A. F. A. Veenhof, Koen J. Hartemink, Liudmila L. Kodach, Vincent van der Noort, Johanna W. van Sandick
Other articles about PERISCOPE II on OncoDaily.